Th17 and cancer: friends or foes?

Adoptive transfer of tumor-reactive CD8+ T lymphocytes is one of the most effective immunotherapy approaches for the treatment of solid tumors.1 Muranski and colleagues show that a recently identified population of CD4+ T lymphocytes called Th17 cells possesses unexpected antimyeloma therapeutic properties